CliffBio
biologic

Ultomiris

ravulizumab-cwvz

Loss of exclusivityOctober 2032projected — 12-year biologic exclusivity estimate
CompanyAlexion Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameUltomiris
Active ingredientravulizumab-cwvz
Strength1,100MG/11ML (100MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalOctober 2020
Marketing statusRx

More from Alexion Pharmaceuticals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Ultomiris patent cliff — loss of exclusivity October 2032 | CliffBio